GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Medeon Biodesign Inc (ROCO:6499) » Definitions » Cyclically Adjusted Revenue per Share

Medeon Biodesign (ROCO:6499) Cyclically Adjusted Revenue per Share : NT$4.02 (As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Medeon Biodesign Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Medeon Biodesign's adjusted revenue per share for the three months ended in Mar. 2024 was NT$0.512. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is NT$4.02 for the trailing ten years ended in Mar. 2024.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2024-06-16), Medeon Biodesign's current stock price is NT$41.90. Medeon Biodesign's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was NT$4.02. Medeon Biodesign's Cyclically Adjusted PS Ratio of today is 10.42.

During the past 12 years, the highest Cyclically Adjusted PS Ratio of Medeon Biodesign was 12.25. The lowest was 9.90. And the median was 11.32.


Medeon Biodesign Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Medeon Biodesign's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medeon Biodesign Cyclically Adjusted Revenue per Share Chart

Medeon Biodesign Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Medeon Biodesign Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Mar24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 4.03 4.02

Competitive Comparison of Medeon Biodesign's Cyclically Adjusted Revenue per Share

For the Medical Instruments & Supplies subindustry, Medeon Biodesign's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medeon Biodesign's Cyclically Adjusted PS Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Medeon Biodesign's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Medeon Biodesign's Cyclically Adjusted PS Ratio falls into.



Medeon Biodesign Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Medeon Biodesign's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.512/131.7762*131.7762
=0.512

Current CPI (Mar. 2024) = 131.7762.

Medeon Biodesign Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201306 0.000 98.518 0.000
201312 0.000 98.326 0.000
201406 0.000 100.560 0.000
201412 0.000 99.070 0.000
201503 0.000 99.621 0.000
201506 0.000 100.684 0.000
201509 0.000 100.392 0.000
201512 0.000 99.792 0.000
201603 0.000 100.470 0.000
201606 0.000 101.688 0.000
201609 0.000 101.861 0.000
201612 0.374 101.863 0.484
201703 0.467 102.862 0.598
201706 0.691 103.349 0.881
201709 0.347 104.136 0.439
201712 0.594 104.011 0.753
201803 5.846 105.290 7.317
201806 0.698 106.317 0.865
201809 0.801 106.507 0.991
201812 1.003 105.998 1.247
201903 1.061 107.251 1.304
201906 1.211 108.070 1.477
201909 1.359 108.329 1.653
201912 1.323 108.420 1.608
202003 1.487 108.902 1.799
202006 0.155 108.767 0.188
202009 0.098 109.815 0.118
202012 0.908 109.897 1.089
202103 0.119 111.754 0.140
202106 0.419 114.631 0.482
202109 0.107 115.734 0.122
202112 0.107 117.630 0.120
202203 2.058 121.301 2.236
202206 0.319 125.017 0.336
202209 0.453 125.227 0.477
202212 0.351 125.222 0.369
202303 0.471 127.348 0.487
202306 0.562 128.729 0.575
202309 0.498 129.860 0.505
202403 0.512 131.776 0.512

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Medeon Biodesign  (ROCO:6499) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Medeon Biodesign's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=41.90/4.02
=10.42

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 12 years, the highest Cyclically Adjusted PS Ratio of Medeon Biodesign was 12.25. The lowest was 9.90. And the median was 11.32.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Medeon Biodesign Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Medeon Biodesign's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Medeon Biodesign (ROCO:6499) Business Description

Traded in Other Exchanges
N/A
Address
No. 116, HouGang Street, 7th Floor, Shilin District, Taipei, TWN, 11170
Medeon Biodesign Inc develops medical device products. The main services of the Group are the research and development of medical devices, manufacturing, and sale of injection molding and components of medical devices. The company provides products in the fields of cardiovascular and laparoscopic. Its business includes Medical Device Development Department and Medical Device Components Manufacturing and Sales Department. The majority of the company revenue comes from Medical Device Components Manufacturing and Sales Department segment. The company revenue is mainly derived from the USA.

Medeon Biodesign (ROCO:6499) Headlines

No Headlines